Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 159 participants.

Also called NCT01190007

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 159 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01190007
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01190007. Non-randomized; no masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2012-02 (actual). Results posted on 2012-12-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
Condition
Hypertension
Condition
Hypercholesterolemia
Condition
Angina Pectoris
Intervention (Drug)
Caduet
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (class: industry)

Record details

Record id
cardio:ct-nct01190007
Content hash
40e25c4a446ae813a299d527bfe030d24b2f9c92ecbf3255246a5f429b145721